适应证持续拓展，HPV疫苗市场竞争“扩围”

上观新闻01-19

就在十多天前，跨国药企默沙东宣布，中国境内首个、可适用于男性的四价HPV疫苗佳达修获批上市。很快，多地就传来了首针落地的消息，上海也已诞生了首批男性HPV疫苗接种者。　　HPV是一种易感染人体表皮和黏膜鳞状上皮的病毒，已被发现有两百多种型别，根据致癌性的不同分为高危型别和低危型别。2017年默沙东四价HPV疫苗在我国上市，一年之后九价HPV疫苗也获批进入国内市场，适用人群范围不断扩大。默沙东全球...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2504657624?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2025-01-19 19:04","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2504657624","market":"us","top_or_hot":-1,"title":"适应证持续拓展，HPV疫苗市场竞争“扩围”","media":"上观新闻","content":"<div>\n<p>就在十多天前，跨国药企默沙东宣布，中国境内首个、可适用于男性的四价HPV疫苗佳达修获批上市。很快，多地就传来了首针落地的消息，上海也已诞生了首批男性HPV疫苗接种者。　　HPV是一种易感染人体表皮和黏膜鳞状上皮的病毒，已被发现有两百多种型别，根据致癌性的不同分为高危型别和低危型别。2017年默沙东四价HPV疫苗在我国上市，一年之后九价HPV疫苗也获批进入国内市场，适用人群范围不断扩大。默沙东全球...</p>\n\n<a href=\"http://finance.eastmoney.com/a/202501193301328243.html\">网页链接</a>\n\n</div>\n","source":"stock_eastmoney","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>适应证持续拓展，HPV疫苗市场竞争“扩围”</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n适应证持续拓展，HPV疫苗市场竞争“扩围”\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-01-19 19:04 北京时间&nbsp;&nbsp;&nbsp;<a href=http://finance.eastmoney.com/a/202501193301328243.html><strong>上观新闻</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>就在十多天前，跨国药企默沙东宣布，中国境内首个、可适用于男性的四价HPV疫苗佳达修获批上市。很快，多地就传来了首针落地的消息，上海也已诞生了首批男性HPV疫苗接种者。　　HPV是一种易感染人体表皮和黏膜鳞状上皮的病毒，已被发现有两百多种型别，根据致癌性的不同分为高危型别和低危型别。2017年默沙东四价HPV疫苗在我国上市，一年之后九价HPV疫苗也获批进入国内市场，适用人群范围不断扩大。默沙东全球...</p>\n\n<a href=\"http://finance.eastmoney.com/a/202501193301328243.html\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU0203347892.USD","symbol_name":"SCHRODER ISF QEP GLOBAL ACTIVE VALLUE \"A\" (USD)  INC AV","start_time":0,"source_url":"http://finance.eastmoney.com/a/202501193301328243.html","article_id":"2504657624","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2504657624","pubTimestamp":1737284681,"columns":[],"sourceInfo":{"source_id":"stock_eastmoney","name":"东方财富"},"weMediaInfo":null,"summary":"就在十多天前，跨国药企默沙东宣布，中国境内首个、可适用于男性的四价HPV疫苗佳达修获批上市。很快，多地就传来了首针落地的消息，上海也已诞生了首批男性HPV疫苗接种者。HPV是一种易感染人体表皮和黏膜鳞状上皮的病毒，已被发现有两百多种型别，根据致癌性的不同分为高危型别和低危型别。","collect":0,"end_time":0,"defaultTopTitle":"eastmoney.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"LU0203347892.USD":"SCHRODER ISF QEP GLOBAL ACTIVE VALLUE \"A\" (USD)  INC AV","IE00BSNM7G36.USD":"NEUBERGER BERMAN SYSTEMATIC GLOBAL SUSTAINABLE VALUE \"A\" (USD) ACC","LU1989771016.USD":"东方汇理环球老龄化投资基金 A2 Acc","BK4585":"ETF&股票定投概念","LU1291159041.SGD":"CPR Invest - Global Silver Age A2 Acc SGD-H","IE00BBT3K403.USD":"LEGG MASON CLEARBRIDGE TACTICAL DIVIDEND INCOME \"A(USD) ACC","SG9999014559.SGD":"United Income Focus Trust Dis SGD","LU1989772840.SGD":"CPR Invest - Climate Action A2 Acc SGD-H","LU2468319806.SGD":"MANULIFE GF HEALTHCARE \"AA\" (SGDHDG) ACC","LU0861579265.USD":"联博低波幅策略股票基金A","LU1093756325.SGD":"FTIF - Franklin K2 Alt Strat Fd A (acc) SGD-H1","LU1037948897.HKD":"AB LOW VOLATILITY EQUITY PORTFOLIO \"AD\" (HKD) INC","LU0289739699.SGD":"AB INTERNATIONAL HEALTH CARE PORTFOLIO \"A\" (SGD) ACC","LU1066051498.USD":"HSBC GIF GLOBAL EQUITY VOLATILITY FOCUSED \"AM2\" (USD) INC","LU1066053197.SGD":"HSBC GIF GLOBAL EQUITY VOLATILITY FOCUSED \"AM3\" (SGDHDG) INC","LU0211331839.USD":"FRANKLIN MUTUAL GLB DISCOVERY \"A\" (USD) ACC","LU1093756168.USD":"FRANKLIN K2 ALTERNATIVE STRATEGIES \"A\" (USD) ACC","LU1069347547.HKD":"AB SICAV I - GLOBAL VALUE PORTFOLIO \"AD\" (HKD) INC","LU2023250504.SGD":"Allianz Thematica Cl AMg DIS H2-SGD","LU0265550359.USD":"BGF SYSTEMATIC GLOBAL ENHANCED EQUITY YIELD \"A2\" (USD) ACC","LU1934455277.USD":"AB SICAV I LOW VOLATILITY TOTAL RETURN EQUITY PORT \"AD\" (USD) INC","IE00BJT1NW94.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"A2\" (SGDHDG) ACC","LU1116320901.HKD":"BGF SYSTEMATIC GLOBAL ENHANCED EQUITY YIELD \"A6\" (HKD) INC","LU1917777945.USD":"安联专题基金Cl AT Acc","LU1037948541.HKD":"AB LOW VOLATILITY EQUITY PORTFOLIO \"A\" (HKD) ACC","LU2089984988.USD":"MANULIFE GF HEALTHCARE \"AA\" (USD) ACC","BK4550":"红杉资本持仓","SG9999014575.USD":"UOB UNITED INCOME FOCUS TRUST FUND (USDHDG) INC","AIN":"奥尔巴尼国际股份有限公司","LU0985320562.USD":"NORDEA 1 GLOBAL STARS EQUITY \"BP\" (USD) ACC","LU0238689110.USD":"贝莱德环球动力股票基金","SG9999002232.USD":"Allianz Global High Payout USD","SG9999015358.SGD":"United Income Focus Trust Dis SGD-H","BK4588":"碎股","LU1116320737.USD":"BGF SYSTEMATIC GLOBAL ENHANCED EQUITY YIELD \"A6\" (USD) INC","SG9999002224.SGD":"Allianz Global High Payout SGD","LU0265550946.USD":"BGF SYSTEMATIC GLOBAL ENHANCED EQUITY YIELD \"A5\" (USD) INC","BK4007":"制药","LU1066051811.HKD":"HSBC GIF GLOBAL EQUITY VOLATILITY FOCUSED \"AM2\" (HKD) INC","LU1934455863.HKD":"AB SICAV I LOW VOLATILITY TOTAL RETURN EQUITY PORT \"A\" (HKD) ACC","LU1061106388.HKD":"BGF WORLD HEALTHSCIENCE \"A2\" (HKDHDG) ACC","IE00B1BXHZ80.USD":"Legg Mason ClearBridge - US Appreciation A Acc USD","IE00BN8TJ469.HKD":"FTGF CLEARBRIDGE TACTICAL DIVIDEND INCOME \"A\" (HKD) INC","SG9999014542.SGD":"United Income Focus Trust Acc SGD","LU0965509101.SGD":"AB LOW VOLATILITY EQUITY PORTFOLIO \"A\" (SGDHDG) ACC","LU1162221912.USD":"FRANKLIN INCOME \"A\" (USD) ACC","LU0070302665.USD":"FRANKLIN MUTUAL U.S. VALUE \"A\" (USD) ACC","IE00B4R5TH58.HKD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"A2\" (HKD) ACC","MRK":"默沙东","LU1974910355.USD":"Allianz Thematica Cl AMg DIS USD"},"translate_title":"Indications continue to expand, and competition in the HPV vaccine market \"expands\"","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"AIN":1,"MRK":0.9},"content_text":"就在十多天前，跨国药企默沙东宣布，中国境内首个、可适用于男性的四价HPV疫苗佳达修获批上市。很快，多地就传来了首针落地的消息，上海也已诞生了首批男性HPV疫苗接种者。　　HPV是一种易感染人体表皮和黏膜鳞状上皮的病毒，已被发现有两百多种型别，根据致癌性的不同分为高危型别和低危型别。2017年默沙东四价HPV疫苗在我国上市，一年之后九价HPV疫苗也获批进入国内市场，适用人群范围不断扩大。默沙东全球高级副总裁、默沙东中国总裁田安娜表示，截至2024年底，默沙东HPV疫苗已保护了5200万中国女性，而HPV男性适应证的获批上市将进一步助力中国公共卫生事业的发展，保护更多男性以及他们的家庭，共建更为牢固的健康防线。　　1月8日，默沙东四价HPV疫苗在中国获批适用于9-26岁男性预防因HPV16、18引起的肛门癌，HPV6和11引起的生殖器疣（尖锐湿疣），以及由HPV6、11、16、18引起的以下癌前病变或不典型病变：1级、2级、3级肛门上皮内瘤样病变（AIN）。　　除了默沙东之外，目前在中国获批上市的HPV疫苗还包括葛兰素史克的二价苗以及两款国产二价苗，分别来自沃森生物和万泰生物，国产四价苗和九价苗也已在路上。在默沙东四价HPV疫苗获批之前，各家HPV疫苗获批的适应证均限于一定年龄的女性，这一市场的竞争激烈程度可想而知，而男性HPV疫苗的落地将带来更多的市场空间。　　国金证券发布的数据显示，若以9岁至45岁年龄段推测，中国潜在的接种目标男性人数超过3亿。开源证券预测，随着HPV疫苗的适应证拓展至男性群体，加之目标人群接种意识的不断提升，中国HPV疫苗市场规模将持续扩大，有望在2031年达到625.4亿元的规模。　　不过，这一空间的拓展难度并不低。目前，大众已逐步认识到HPV感染对女性所造成的疾病威胁，几乎所有的宫颈癌（99.7%）都与HPV感染有关。事实上，HPV感染对于男性也构成不容忽视的影响与疾病威胁。根据相关数据显示，88%肛门癌归因于HPV持续感染。尖锐湿疣是指由人类乳头瘤病毒（HPV）引起的生殖器疣，容易复发，且约90%的生殖器疣与低危型HPV6和HPV11感染有关。　　中国疾病预防控制中心性病控制中心临床防治室主任、中国医学科学院皮肤病医院王千秋教授介绍说，HPV传播方式为多途径的直接或间接接触，外伤或皮肤破损也是HPV感染的重要因素。全球数据显示，男性青少年时期的HPV感染率较高，15-19岁男性生殖器HPV感染率达28%。接种HPV疫苗是预防HPV相关疾病的有效手段之一，是防控HPV感染相关疾病的一级预防措施。　　复旦大学公共卫生学院教授、上海市学校卫生保健协会会长傅华表示，“研究结果证实，男女共防HPV感染可以帮助降低HPV感染率及相关疾病发病率，同时有助于实现加速消除宫颈癌的目标，是实现群体免疫的重要方向。这既符合公平原则，也能有效降低社会整体医疗负担。”　　记者还了解到，默沙东已在国内启动多项HPV疫苗新适应证的临床试验，旨在深入探索HPV疫苗在各类人群中预防HPV相关疾病的潜力，推动男女共同防治的策略。（文章来源：上观新闻）","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.35.9","shortVersion":"4.35.9","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2504657624","isCrawlerRequest":true}